Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Taspoglutide"'
Autor:
B Dharmaraj
Publikováno v:
International Journal of Preclinical and Clinical Research. 1:26-34
GLP-1 (Glucagon like Peptide-1) receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, Exenatide, was approved in the year 2000, other agents with a longer dur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d0e74125d73999748b2dc0dddb3d095
https://doi.org/10.51131/ijpccr/v1i1.7
https://doi.org/10.51131/ijpccr/v1i1.7
Autor:
Lehar Khanna, Perica Davitkov, Larry J. Prokop, Katayoun Khoshbin, Kia Vosoughi, Michael J. Camilleri, Jessica Atieh, M. Hassan Murad
Publikováno v:
EClinicalMedicine, Vol 42, Iss, Pp 101213-(2021)
EClinicalMedicine
EClinicalMedicine
Background: Comparative effectiveness of 7 glucagon-like peptide 1 (GLP-1) agents on weight loss (WL) in obesity is unknown. Methods: Study Design: Systematic review, network meta-analysis (NMA) Data Sources: MEDLINE, EMBASE, Scopus, Cochrane Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6a5f9a5a0e9230cdeb0c87c4fe85fe3
http://www.sciencedirect.com/science/article/pii/S2589537021004946
http://www.sciencedirect.com/science/article/pii/S2589537021004946
Autor:
Patrick M. Sexton, Yi Lynn Liang, Radostin Danev, Denise Wootten, Matthew J. Belousoff, Xin Zhang
SUMMARYThe glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism and appetite, and is an important target for treatment of type II diabetes and obesity. Multiple GLP-1R agonists have entered into clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b595151093b6a5b9b7987b7e2362c6c
https://doi.org/10.1101/2021.01.12.426449
https://doi.org/10.1101/2021.01.12.426449
Autor:
Xin Zhang, Patrick M. Sexton, Yi Lynn Liang, Denise Wootten, Radostin Danev, Matthew J. Belousoff
Publikováno v:
Cell Reports, Vol 36, Iss 2, Pp 109374-(2021)
Summary: The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism, and appetite and is an important target for treatment of type 2 diabetes and obesity. Multiple GLP-1R agonists have entered into clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24add099cb0536b8b9a8494936633129
https://pubmed.ncbi.nlm.nih.gov/34260945
https://pubmed.ncbi.nlm.nih.gov/34260945
Autor:
Kamlesh Khunti, Zin Zin Htike, Melanie J. Davies, David R. Webb, Dimitris Papamargaritis, Francesco Zaccardi
Publikováno v:
Diabetes, Obesity and Metabolism. 19:524-536
Aims To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34e029818afa702280ad2cdf8301fc47
https://doi.org/10.1111/dom.12849
https://doi.org/10.1111/dom.12849
Autor:
Markus Niggli, Christophe Schmitt, Mylene Giraudon, Nathalie Lambert, Bernhard Mangold, Stefan Sturm, Jochen Brumm
Publikováno v:
Diabetes, Obesity and Metabolism. 19:537-544
Aim To evaluate single-dose pharmacokinetics and tolerability of taspoglutide in people with varying degrees of renal impairment and matched healthy participants. Methods Participants in the present study were people with mild renal impairment (n = 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dbf84c40ae6abb9e6f913f9cbc79f42
https://doi.org/10.1111/dom.12850
https://doi.org/10.1111/dom.12850
Autor:
Katrijn Bogman, Stefan Sturm, Jochen Brumm, Mylene Giraudon, Bernhard Mangold, Markus Niggli, Carolina Sturm-Pellanda, Carsten Hofmann, Annette Sauter, Christophe Schmitt
Publikováno v:
Clinical pharmacokinetics. 58(9)
Taspoglutide, a glucagon-like peptide-1 agonist, like native glucagon-like peptide-1, delays gastric emptying time and prolongs intestinal transit time, which may alter the pharmacokinetics of concomitantly administered oral drugs. The effect of tasp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fac9e776b6215ffadd82cb4da99295bf
https://pubmed.ncbi.nlm.nih.gov/30968335
https://pubmed.ncbi.nlm.nih.gov/30968335
Autor:
Sten Madsbad
Publikováno v:
Diabetes, Obesity & Metabolism
Currently, six glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for treating type 2 diabetes. These fall into two classes based on their receptor activation: short-acting exenatide twice daily and lixisenatide once daily; and longer-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d79681390b5d06821f2752a84e88d84
http://europepmc.org/articles/PMC5064617
http://europepmc.org/articles/PMC5064617
Autor:
Rakesh Sahay, Ambika Gopalakrishnan Unnikrishnan, Sanjay Kalra, Manash P Baruah, O. Adetunji, Shweta Uppal
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 20, Iss 2, Pp 254-267 (2016)
Indian Journal of Endocrinology and Metabolism
Indian Journal of Endocrinology and Metabolism
Glucagon-like peptide-1 (GLP-1)-based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f36abc2f2c280afbe0a478516f79b7
http://www.ijem.in/article.asp?issn=2230-8210
http://www.ijem.in/article.asp?issn=2230-8210
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 292
Agonists of the glucagon-like peptide-1 (GLP-1) receptor and analogs of human amylin have been studied for almost two decades due to their therapeutic potential to treat diabetes mellitus and obesity. Both native peptides exhibit unfavorable pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b04ddf5d651eead1caef86483892253
https://pubmed.ncbi.nlm.nih.gov/29729352
https://pubmed.ncbi.nlm.nih.gov/29729352